Pieris Looks For Way Out After AstraZeneca Exits Respiratory Collaboration
Will Cut Workforce By 70%
The US biotech is hoping to either partner off its wholly owned pipeline or become a target for an acquisition or merger after AstraZeneca’s asthma exit left it with dwindling cash, and a need to cut costs.
